What do systematic reviews say?

TG4010 added to chemotherapy vs chemotherapy alone

The review found no eligible studies for this question.

• Therapeutic vaccines for advanced non‐small cell lung cancer 2024 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Intervention not reported

The intervention may leads to higher quality of life (low certainty).

• Chemotherapy versus best supportive care for extensive small cell lung cancer 2013 · Cochrane Headline outcomes only
  RR 2.18 [0.05, 0.25]
  1 study · 141 participants
  Low

Intervention not reported

• Chemotherapy with cetuximab versus chemotherapy alone for chemotherapy‐naive advanced non‐small cell lung cancer 2014 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 1801 participants
  Low

Non‐platinum therapies vs platinum combination

• Chemotherapy for advanced non‐small cell lung cancer in the elderly population 2015 · Cochrane Headline outcomes only
  no estimate extracted
  5 studies · 5 participants
  GRADE not reported

Non‐platinum single‐agent vs non‐platinum combination treatment

• Chemotherapy for advanced non‐small cell lung cancer in the elderly population 2015 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 2 participants
  GRADE not reported

ALK inhibitor vs any cytotoxic chemotherapy

ALK inhibitor leads to lower health‐related quality of life: time to deterioration in composite… compared with any cytotoxic chemotherapy (high certainty).

• Targeted therapy for advanced anaplastic lymphoma kinase (ALK)‐rearranged non‐small cell lung cancer 2022 · Cochrane Headline outcomes only
  HR 0.52 [0.44, 0.6]
  5 studies · 1504 participants
  High